Search Results

Saudi Arabia is building the regulatory framework, partnerships infrastructure and IP landscape needed to support a biotech ecosystem, despite regional political instability. Whether it can produce sustainable biotech companies and a resilient manufacturing base for global production remains an open question, but the future looks bright.

Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.

Founded by a former biotech finance professional, biosuite helps smaller biotech teams track financial commitments to research partners before the corresponding invoices arrive.

BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.

A new proposal from the U.S. government seeking to address investment in Chinese biotech as a matter of national security drew cautious statements from across the industry, with leaders vowing to ensure innovation isn’t stifled.

Belgium and the Netherlands have built some of Europe’s strongest life sciences ecosystems, powered by leading research institutions and a growing pool of experienced biotech talent. While early-stage funding remains scarce and investment is often fragmented across regions, investors see national biotech initiatives and broader EU support as catalysts for future growth.

Biotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.